Latest News on Sanofi Aventis
Showing of 0 - 10 from 8 results
Sanofi Aventis - Total results - 8
Dec 11, 2013
India Inc strikes deals worth nearly $27 bn in last 11 monthsAccording to assurance, tax and advisory firm Grant Thornton, corporates in the country announced 458 deals in the January-November period amounting to USD 26.76 billion.
Feb 16, 2013
Shantha Biotech buyout: Sanofi to pay tax in France not IndiaThe Andhra Pradesh High Court today ruled that French drug maker Sanofi Aventis will not have to pay taxes in India for its buyout of Hyderabad-based vaccine firm Shantha Biotechnics in 2009.
Oct 17, 2012
Lupin gets USFDA approval for hypertension pillsPharma major Lupin Wednesday said it has got approval from the US Food and Drugs Administration (FDA) to market generic versions of Sanofi Aventis' Avapro tablets, prescribed in the treatment of hypertension and nephropathy in Type-II diabetis.
Sep 11, 2012
Dengue vaccine possible, though not any time soonInital trials of the dengue vaccine that were carried out in Thailand have been less than encouraging with only 30 percent efficacy and more research will be required.
Jun 08, 2012
Cipla loses US court appeal over animal healthcare productPharmaceuticals major Cipla lost an appeal in the US court against Merial ltd, a subsidiary of Sanofi-Aventis for an animal healthcare product. Merial took Cipla to court saying the product infringed on a patent owned by Merial.
Aug 26, 2011
Earnings blow fails to deter M&A flow for Corporate IndiaThe market too has nothing positive to offer. But the companies are high on inorganic growth and don't mind taking the bull by the horns.
May 17, 2011
Sanofi deal creates buzz for Glenmark; re-rating likelyMacquarie finds Glenmark's valuation attractive and feels the market is not assigning any value to the company's innovation franchise because of a few setbacks in the past.
May 16, 2011
Weak European markets and inflation data play spoilsportWeak opening by European markets and higher than expected inflation numbers pull the markets down further.